July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Analysis of the serum and aqueous humor levels of IL-6 in patients with neovascular (wet) age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor A monotherapy
Author Affiliations & Notes
  • Eric Wakshull
    Genentech, Inc, South San Francisco, California, United States
  • Kyu Hong
    Genentech, Inc, South San Francisco, California, United States
  • Bann-mo Day
    Genentech, Inc, South San Francisco, California, United States
  • Min Bao
    Genentech, Inc, South San Francisco, California, United States
  • Hugh Lin
    Genentech, Inc, South San Francisco, California, United States
  • Ivaylo Stoilov
    Genentech, Inc, South San Francisco, California, United States
  • Footnotes
    Commercial Relationships   Eric Wakshull, Genentech, Inc. (E); Kyu Hong, Genentech, Inc. (E); Bann-mo Day, Genentech, Inc. (E); Min Bao, Genentech, Inc. (E); Hugh Lin, Genentech, Inc (E); Ivaylo Stoilov, Genentech, Inc. (E), Genentech, Inc. (I)
  • Footnotes
    Support  Genentech, Inc., South San Francisco, CA, provided support for the study and participated in the study design; conducting the study; and data collection, management, and interpretation.
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 1456. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eric Wakshull, Kyu Hong, Bann-mo Day, Min Bao, Hugh Lin, Ivaylo Stoilov; Analysis of the serum and aqueous humor levels of IL-6 in patients with neovascular (wet) age-related macular degeneration (nAMD) receiving anti-vascular endothelial growth factor A monotherapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):1456.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Interleukin 6 (IL-6) is a proinflammatory cytokine implicated in the pathogenesis of various intraocular vascular diseases. The objectives of this study were to measure and compare IL-6 levels of patients enrolled in the HARBOR trial of ranibizumab (RBZ) in nAMD, and to describe the vision outcomes with RBZ in the patients with IL-6 data.

Methods : This retrospective analysis of the phase 3 HARBOR study (NCT00891735) included patients who had matching aqueous humor and serum samples collected at month 2 of study. IL-6 levels were measured using a proprietary multiplex chip technology and IL-6 distribution in aqueous vs. serum at month 2 were compared using the Wilcoxon rank-sum test. Since aqueous and serum samples were collected after the third dose of RBZ at month 2, Early Treatment Diabetic Retinopathy Study (ETDRS) letter score at month 2 was used as the baseline to calculate best-corrected visual acuity (BCVA) change for each patient over the course of the study. Mean BCVA change from month 2 was compared for groups of patients stratified by their aqueous IL-6 levels.

Results : In total, 36 patients had matching aqueous and serum samples (all white and 61% female) with fewer classic lesions compared with the overall HARBOR population (6% vs. 16%). Median IL-6 levels were higher in the aqueous humor compared with serum [6 pg/mL (range <1 to 55.7) vs. 3.5 pg/mL (range <1 to 19.1); P=0.005]. Patients with aqueous IL-6 ≥15 pg/mL (n=9) on average lost 9 letters at month 24 while patients with IL-6 <15 pg/mL (n=27) gained 2.9 letters. These findings were consistent across a range of cutoffs for IL-6 (6 to 15 pg/mL). Differences in vision outcomes are descriptive and did not reach statistical significance.

Conclusions : The results from this HARBOR substudy suggest that in patients with nAMD, aqueous IL-6 levels are higher and exhibit a broader distribution compared to serum levels, which may allow patient stratification. There was no correlation between aqueous and serum IL-6 levels. These results should be interpreted with caution due to the small number of patients and the post hoc nature of the analysis.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×